Eco-friendly synthesis and biomedical potential of zinc oxide nanoparticles using Mentha piperita aqueous extract: comparative analysis with chemically synthesized and commercial nanoparticles.

IF 3.5 3区生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Bioprocess and Biosystems Engineering Pub Date : 2025-05-24 DOI:10.1007/s00449-025-03178-6

Roberta A Dos Reis, Leonardo L da Silva, Joana C Pieretti, Benjamin Creusot, Sephora Lahouari, Gregory Francius, Ricardo A G da Silva, Igor Clarot, Ariane Boudier, Amedea B Seabra

{"title":"Eco-friendly synthesis and biomedical potential of zinc oxide nanoparticles using Mentha piperita aqueous extract: comparative analysis with chemically synthesized and commercial nanoparticles.","authors":"Roberta A Dos Reis, Leonardo L da Silva, Joana C Pieretti, Benjamin Creusot, Sephora Lahouari, Gregory Francius, Ricardo A G da Silva, Igor Clarot, Ariane Boudier, Amedea B Seabra","doi":"10.1007/s00449-025-03178-6","DOIUrl":null,"url":null,"abstract":"<p><p>Phytosynthesis of zinc oxide nanoparticles (ZnO NPs) using Mentha piperita extract offers a sustainable alternative for biomedical applications. This study investigates the synthesis, characterization, and biological properties of biosynthesized ZnO (ZnO Bio NPs) compared to chemically synthesized (ZnO Chem NPs) and commercial ZnO (ZnO Commercial NPs). We explored how peppermint's phytochemicals influence ZnO NP synthesis and biological interactions. Peppermint-derived phytochemicals act as reducing and stabilizing agents while providing antioxidant and anticarcinogenic benefits, potentially enhancing ZnO Bio NPs' therapeutic effects. Our findings reveal that ZnO Bio NPs exhibit superior stability and bioactivity due to plant-based capping agents. ZnO Bio NPs inhibited 52% of DPPH radicals at 15.63 µg/mL, outperforming ZnO Chem and Commercial NPs. In hemocompatibility studies, ZnO Bio NPs showed minimal hemolysis, both with and without protein corona (albumin and fibrinogen), ensuring safer blood interactions. Cytotoxicity assays demonstrated that ZnO Bio NPs had an IC50 of 49.91 µg/mL in human fibroblasts, threefold less cytotoxic than ZnO Commercial NPs. These results highlight the potential of peppermint-extract-based ZnO NPs for biomedical applications, offering lower cytotoxicity and greater biocompatibility while providing an eco-friendly alternative to conventional synthesis methods.</p>","PeriodicalId":9024,"journal":{"name":"Bioprocess and Biosystems Engineering","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioprocess and Biosystems Engineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1007/s00449-025-03178-6","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Phytosynthesis of zinc oxide nanoparticles (ZnO NPs) using Mentha piperita extract offers a sustainable alternative for biomedical applications. This study investigates the synthesis, characterization, and biological properties of biosynthesized ZnO (ZnO Bio NPs) compared to chemically synthesized (ZnO Chem NPs) and commercial ZnO (ZnO Commercial NPs). We explored how peppermint's phytochemicals influence ZnO NP synthesis and biological interactions. Peppermint-derived phytochemicals act as reducing and stabilizing agents while providing antioxidant and anticarcinogenic benefits, potentially enhancing ZnO Bio NPs' therapeutic effects. Our findings reveal that ZnO Bio NPs exhibit superior stability and bioactivity due to plant-based capping agents. ZnO Bio NPs inhibited 52% of DPPH radicals at 15.63 µg/mL, outperforming ZnO Chem and Commercial NPs. In hemocompatibility studies, ZnO Bio NPs showed minimal hemolysis, both with and without protein corona (albumin and fibrinogen), ensuring safer blood interactions. Cytotoxicity assays demonstrated that ZnO Bio NPs had an IC50 of 49.91 µg/mL in human fibroblasts, threefold less cytotoxic than ZnO Commercial NPs. These results highlight the potential of peppermint-extract-based ZnO NPs for biomedical applications, offering lower cytotoxicity and greater biocompatibility while providing an eco-friendly alternative to conventional synthesis methods.

查看原文本刊更多论文

薄荷水萃取物氧化锌纳米粒子的生态合成及其生物医学潜力：与化学合成纳米粒子和商业纳米粒子的比较分析。

利用薄荷提取物合成氧化锌纳米粒子（ZnO NPs）为生物医学应用提供了一种可持续的选择。本研究研究了生物合成ZnO （ZnO Bio NPs）的合成、表征和生物学性能，并与化学合成ZnO （ZnO Chem NPs）和商业ZnO （ZnO commercial NPs）进行了比较。我们探讨了薄荷植物化学物质如何影响ZnO NP合成和生物相互作用。薄荷衍生的植物化学物质作为还原剂和稳定剂，同时提供抗氧化和抗癌的好处，潜在地增强ZnO Bio NPs的治疗效果。我们的研究结果表明，由于植物基封盖剂，ZnO Bio NPs具有优越的稳定性和生物活性。ZnO Bio NPs在15.63µg/mL时抑制了52%的DPPH自由基，优于ZnO Chem和商用NPs。在血液相容性研究中，ZnO Bio NPs在有和没有蛋白冠（白蛋白和纤维蛋白原）的情况下都显示出最小的溶血，确保了更安全的血液相互作用。细胞毒性实验表明，ZnO Bio NPs在人成纤维细胞中的IC50为49.91µg/mL，比ZnO Commercial NPs的细胞毒性低3倍。这些结果突出了薄荷提取物为基础的ZnO NPs在生物医学应用中的潜力，它具有更低的细胞毒性和更高的生物相容性，同时为传统的合成方法提供了一种环保的替代方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bioprocess and Biosystems Engineering 工程技术-工程：化工

CiteScore

7.90

自引率

2.60%

发文量

147

审稿时长

2.6 months

期刊介绍： Bioprocess and Biosystems Engineering provides an international peer-reviewed forum to facilitate the discussion between engineering and biological science to find efficient solutions in the development and improvement of bioprocesses. The aim of the journal is to focus more attention on the multidisciplinary approaches for integrative bioprocess design. Of special interest are the rational manipulation of biosystems through metabolic engineering techniques to provide new biocatalysts as well as the model based design of bioprocesses (up-stream processing, bioreactor operation and downstream processing) that will lead to new and sustainable production processes. Contributions are targeted at new approaches for rational and evolutive design of cellular systems by taking into account the environment and constraints of technical production processes, integration of recombinant technology and process design, as well as new hybrid intersections such as bioinformatics and process systems engineering. Manuscripts concerning the design, simulation, experimental validation, control, and economic as well as ecological evaluation of novel processes using biosystems or parts thereof (e.g., enzymes, microorganisms, mammalian cells, plant cells, or tissue), their related products, or technical devices are also encouraged. The Editors will consider papers for publication based on novelty, their impact on biotechnological production and their contribution to the advancement of bioprocess and biosystems engineering science. Submission of papers dealing with routine aspects of bioprocess engineering (e.g., routine application of established methodologies, and description of established equipment) are discouraged.